SignalXSignalX

CC Chemours Co

Q3 2025 10-Q
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Chemicals & Allied ProductsSEC EDGAR
Chemours Co Overview

Chemours Co (CC) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • Newly added environmental compliance risk triggered by evolving U.S. and international laws including CERCLA, TSCA, EU REACH, and China MEE Order No. 12
  • • Updated environmental remediation costs risk with accrual uncertainties due to site complexity, contamination extent, and PRP outcomes
+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$1.5B

Net Income

$60M

Gross Margin

15.5%

Net Margin

4.0%

ROE

20.1%

Total Assets

$7.6B

Source: XBRL data from Chemours Co Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Chemours Co

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.